Trial design and participants
VKH disease, uveitis, Uveitis
REMISSION, UVEITIS, UVEITIS
The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University approved the trial. All trial procedures adhered to the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. This trial was conducted at Uveitis Center of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. This academic, university-affiliated, teaching hospital has set up the large, specialized medical center for uveitis care, having provided service to a total of 2079 VKH disease from 32 provincial administrative regions across mainland China as of 2018Adult patients (≥18 years) who had active VKH disease within the last 90 days and/or had a justification for remission induction with chronic oral prednisone at 20 mg per day or greater were eligible to participate